



## IDEAYA Biosciences and Cancer Research UK Announce Partnership Agreement to Develop Small Molecule Inhibitors of PARG

March 13, 2018

Data related to PARG program to be presented at American Association of Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and LONDON, March 13, 2018 /PRNewswire/ -- IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies, today announced that it has entered into a partnership agreement with Cancer Research UK's (CRUK) Commercial Partnerships Team and the Drug Discovery Unit at the Cancer Research UK Manchester Institute, part of the University of Manchester, UK, to develop small molecule inhibitors of Poly(ADP-ribose) glycohydrolase (PARG). PARG is a cellular enzyme that breaks down Poly(ADP-ribose), a post-translational modification that modulates protein function required for DNA repair. Inhibition of PARG in cancer cells with highly-active PARP results in depletion of cellular NAD. NAD is an essential cofactor in cellular respiration, and its depletion results in a dramatic decrease in cellular ATP and cancer cell death.

"We are thrilled to be able to partner with one of the leading cancer research institutions in CRUK, who has had a prolific history in the space of DNA repair, including its scientific contributions to PARP biology and its associated biomarker BRCA," said Yujiro S. Hata, chief executive officer of IDEAYA. "We look forward to collaborating with this exceptional organization as we advance novel, small molecule inhibitors of PARG towards the clinic."

"The Drug Discovery Unit at the Cancer Research UK Manchester Institute are delighted to be working alongside IDEAYA to further develop our PARG inhibitor program," said Allan Jordan, head of chemistry in the Drug Discovery Unit. "Stemming from fundamental biological discoveries made in our own Institute, PARG inhibitors offer a new way of compromising the ability of cancer cells to survive and resist treatment. We believe that these agents will offer a truly novel and clinically meaningful therapy for patients fighting against cancer."

"This new collaboration with IDEAYA, a leading biotechnology company, will accelerate the translation of discoveries from one of our major drug discovery units," said Iain Foulkes, Ph.D., Cancer Research UK's executive director of research and innovation. "We're excited to focus our combined expertise on this unique program of research. This is one of several partnerships in our growing portfolio of projects that we hope will result in vital new treatments for cancer patients."

IDEAYA and Cancer Research UK also announced today that data from the PARG program will be presented at the American Association of Cancer Research (AACR) Annual Meeting to be held April 14-18, 2018 in Chicago, IL. The presentation details are as follows:

**Title:** PARG inhibitors exhibit synthetic lethality with XRCC1 deficiency and a cellular mechanism of action that is distinct from PARP inhibition

**Date and Time:** Monday, April 16, 8:00 AM - 12:00 PM CDT

**Abstract Number:** 1943

**Presenting author:** Lisa Belmont, Ph.D.

**Session Category:** Experimental and Molecular Therapeutics

### About IDEAYA Biosciences

IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism and innate immunity. IDEAYA, headquartered in South San Francisco, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology, immunology, and small molecule drug discovery. For more information, please visit [www.ideayabio.com](http://www.ideayabio.com).

### About Cancer Research UK's Commercial Partnerships Team

Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research. Our specialist Commercial Partnerships Team works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. The team develop promising ideas into successful cancer therapeutics, software, devices, diagnostics and enabling technologies. This helps to accelerate progress in exciting new discoveries in cancer research and bring new treatments to patients sooner.

Cancer Research UK's commercial activity operates through Cancer Research Technology Ltd. (CRT), a wholly owned subsidiary of Cancer Research UK. It is the legal entity which pursues drug discovery research in themed alliance partnerships and delivers varied commercial partnering arrangements. Visit <http://commercial.cancerresearchuk.org/>

### About Cancer Research UK

- Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
- Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.

- Cancer Research UK receives no funding from the UK government for its life-saving research. Every step it makes towards beating cancer relies on vital donations from the public.
- Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 40 years.
- Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.

*For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit [www.cancerresearchuk.org](http://www.cancerresearchuk.org). Follow us on [Twitter](#) and [Facebook](#).*

### **About The University of Manchester**

The University of Manchester, a member of the prestigious Russell Group, is the UK's largest single-site university with more than 40,000 students – including more than 10,000 from overseas. It is consistently ranked among the world's elite for graduate employability.

The University is also one of the country's major research institutions, rated fifth in the UK in terms of 'research power' (REF 2014). World-class research is carried out across a diverse range of fields including cancer, advanced materials, addressing global inequalities, energy and industrial biotechnology.

No fewer than 25 Nobel laureates have either worked or studied here.

It is the only UK university to have social responsibility among its core strategic objectives, with staff and students alike dedicated to making a positive difference in communities around the world.

Manchester is ranked 38th in the world in the Academic Ranking of World Universities 2017 and 6th in the UK.

Visit [www.manchester.ac.uk](http://www.manchester.ac.uk) for further information.

Facts and figures: <http://www.manchester.ac.uk/discover/facts-figures/>

Research Beacons: <http://www.manchester.ac.uk/research/beacons/>

News and media contacts: <http://www.manchester.ac.uk/discover/news/>

### **Cancer**

Cancer is one of The University of Manchester's research beacons - examples of pioneering discoveries, interdisciplinary collaboration and cross-sector partnerships that are tackling some of the biggest questions facing the planet. #ResearchBeacons